Goldman Sachs is out with a research note this morning, where it suggests that traders buy calendar spreads on Aruba Networks (NASDAQ: UTHR) ahead of upcoming positive Phase 3 data.
Goldman Sachs Biotechnology analyst, Terence Flynn, rates UTHR shares Buy and sees 19% upside to his 12-month price target of $82. He rates UTHR a M&A probability of 1 (strong, 30% - 50% probability in one year) once results from Phase 3 data on their upcoming Pulmonary Arterial Hypertension (PAH) are released this year.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Goldman suggests buying the August $75.00 call and selling the January 2012 $90.00 call for a net debit of $1.45
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the medical needs of patients with chronic diseases.